AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.
Specifically, the company will reinforce its current partnership with Daiichi Pharmaceutical. Further, AnGes MG has decided to place the highest priority on development in the field of peripheral arterial disease in Japan.
Regarding overseas development, AnGes MG will proceed with research in both peripheral arterial disease (PAD) and ischemic heart disease (IHD).
Currently, AnGes MG and Daiichi Pharmaceutical are jointly undertaking phase II and III clinical trials for PAD overseas and in Japan, respectively, and phase I and pre-clinical trials for IHD overseas and in Japan, respectively.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jun 8, 2006|
|Previous Article:||AnGes MG Announces Results of Phase II Clinical Trials of HGF Gene Medicine.|
|Next Article:||Lion, Ota Sleep Center Elucidate that Tomato Vinegar Helps Improve Sleep Quality.|